Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave Technologies, GenVault

Premium

Third Wave Technologies launched its Invader hepatitis C virus genotyping reagents. The product enables clinical labs to develop assays that identify all six genotypes of the HCV virus. Physicians prescribe the test to choose a therapy, determine disease progression, and track drug response.


GenVault launched a lab-scale DNA storage system, and said the Intramural Research Program of the National Institute on Aging has ordered two of the platforms.

The NIA uses GenVault’s 384-well microplates, called GenPlates, which hold DNA in a format that can be stored and shipped at room temperature without special biohazard labeling and treatment. (GenVault said data show that DNA is “stably preserved” in this form and that it may be extracted and purified “with a few buffer washes.”

Filed under

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.